WO1989003674A1 - Microspheres, procede de production des microspheres et leur utilisation - Google Patents
Microspheres, procede de production des microspheres et leur utilisation Download PDFInfo
- Publication number
- WO1989003674A1 WO1989003674A1 PCT/SE1988/000560 SE8800560W WO8903674A1 WO 1989003674 A1 WO1989003674 A1 WO 1989003674A1 SE 8800560 W SE8800560 W SE 8800560W WO 8903674 A1 WO8903674 A1 WO 8903674A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microspheres
- microspheres according
- polymer
- producing
- superparamagnetic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/02—Separating microorganisms from their culture media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G01N33/5434—Magnetic particles using magnetic particle immunoreagent carriers which constitute new materials per se
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/548—Carbohydrates, e.g. dextran
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/12—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar
- G01N2400/14—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar alpha-D-Glucans, i.e. having alpha 1,n (n=3,4,6) linkages between saccharide units, e.g. pullulan
- G01N2400/16—Starch, amylose, amylopectin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2446/00—Magnetic particle immunoreagent carriers
- G01N2446/20—Magnetic particle immunoreagent carriers the magnetic material being present in the particle core
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2446/00—Magnetic particle immunoreagent carriers
- G01N2446/30—Magnetic particle immunoreagent carriers the magnetic material being dispersed in the polymer composition before their conversion into particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2446/00—Magnetic particle immunoreagent carriers
- G01N2446/80—Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
- G01N2446/84—Polymer coating, e.g. gelatin
Definitions
- This invention relates to a method for fabrication of covalently crosslinked microspheres where the matrix material consists of polymers, stabilized into a three dimensional network by crosslinking.
- Microspheres according to this invention may be used within medical diagnostics, cell separation, drug targeting or as slow release systems for drugs. Within some of these areas a magnetically responsive material may be entrapped into the microspheres.
- Microspheres or particles having a size of a few micrometers has been used for more than 60 years for studies within medical diagnostics, in particular in studying the reticuloendothelial functions.
- particles with associated radioactive substances has been used to study the liver, spleen, bone marrow and the lymphatic system and in investigations of the gastrointestinal tract, control of catheters and clinically in the treatment of certain tumors.
- microspheres with entrapped X-ray contrast agents for the use in diagnostics.
- the goal is to achieve a microsphere having a size of 2 ⁇ m which may be injected into the blood stream.
- Such a microsphere would thus be useable as a specific contrast agent for the reticuloendothelial system (RES).
- RES reticuloendothelial system
- the primarily interest is in obtaining a microsphere that could be used as a contrast agent for the liver.
- Microspheres may also be used within cell biology. After associating the microsphere with a fluorescent dye, or any other detectable substance, and then on the surface attach an antibody, it is possible to use the microspheres in the analysis of a certain cell type in a heterogeneous mixture of cells.
- the invention may also be used in the production and the use of slow release systems of biologically active substances taking advantage of a process that allows entrappment of the biologically active substance in a matrix system which is biodegradable and biocompatible. After injection to e.g. a human being, the entrapped substance is released in a predetermined way.
- the biologically active substances maybe hormones such as insulin, growth hormone, calcitonin, ACTH or the like. Other substances can be normal drugs or antigens for the use in vaccination.
- pharmaceutical substance and “drug” are used in its broadest sense, such as abiologically active substance which has an effect and/or is used within the areas mentioned above.
- Substances used for disorders in the lungs cough relaxation (e.g. noskapin) or opiates (e.g. ethylmorfine), drugs reducing swelling of the mucus membrane (e.g. ephedrin, terbutalin, theophylline).
- cough relaxation e.g. noskapin
- opiates e.g. ethylmorfine
- drugs reducing swelling of the mucus membrane e.g. ephedrin, terbutalin, theophylline.
- glycosides such as digoxin, lidocaine and prokainamide.
- Beta-blocking agents such as alprenolol or metoprolol.
- Other groups includes alfa-blocking agents (e.g. phentolamine), beta-stimulators (e.g. bametan), alkylnitrates, calciumantagonists (e.g. nifedepin), derivatives of nicotinic acid, adrenergic compounds (e.g. adrenalin), sympaticusrelaxatives (e.g. guanetidin), ganglieblockers (e.g. trimetafan), hydrazinderivatives, tiazidederivatives, benquentfonamidederivatives, bumetamid, furosemid, ethacrynic acid, spironlacton.
- alfa-blocking agents e.g. phentolamine
- beta-stimulators e.g. bametan
- alkylnitrates e.g. calciumantagonists (
- Varix treatment e.g. polidokanol
- cholesterol synthesis blockers e.g. clofibrate
- Antihistaminic drugs e.g. terbutalin
- Spasmolytic drugs e.g., papaverinderivatives, anticholinergic drugs (e.g, atropin), cholinergic drugs (e.g. carbacol).
- anticholinergic drugs e.g, atropin
- cholinergic drugs e.g. carbacol
- Drugs for tumor treatment vitamins (e.g. B-12 or fblic acid), alkylating substances (e.g. cyclofosfamide), antimetaibolites (e.g. metotrexate or 5-fluorouracil), antibiotics (e.g. daunomycin, bleomycin), mitos blockers (e.g. vinblastin), cisplatinum, nitrousurea derivatives, estramustin, steroidderivatives, cimetidin.
- vitamins e.g. B-12 or fblic acid
- alkylating substances e.g. cyclofosfamide
- antimetaibolites e.g. metotrexate or 5-fluorouracil
- antibiotics e.g. daunomycin, bleomycin
- mitos blockers e.g. vinblastin
- cisplatinum nitrousurea derivatives, estramustin, steroidderivatives, c
- Chemotherapeutic and antibiotic substances sulfonamides, penicillines, cephalosporines, tetracyclines, aminoglycosides, aminosalicylic acid derivatives, isonicotinic acid derivatives, iodine,
- Malaria drugs e.g. chlorokin
- Proteins or peptides Proteins or peptides; digestion enzymes, coagulation factors, immuno globulins, vaccines, hormones,
- Immune stimulating substances e.g. interferons, interleukins.
- Various drugs used in psychiatric treatment Antiepileptic drugs and drugs used to obtain muscle relaxation.
- Antichohnergic drugs, analgetic drugs and anesthetic drugs are not to any extent limited to the examples mentioned above, the substances can be, and has been, used in and with other indications than the above mentioned.
- a pharmaceutical formulation such as described in this invention, is of particular interest, if it would be possible to produce a microsphere with entrapped biologically active substances, having a size that allows inhalation, e.g. formulated as a spray.
- the size of spheres should thus be 1-3 ⁇ m.
- nicotinic acid Another substance having a growing interest is nicotinic acid due to the positive effects seen in the treatment of certain tumors.
- carbohydrate polymers containing ⁇ (1-> 4) bonds exhibit all the prerequisite for a polymer to be used as a pharmaceutical formulation matrix for biologically active substances.
- Starch is a mixture of polymers where the monomers are glucose. The glucose monomers are linked together by ⁇ (1->4) bonds in the linear polymer chains. After fractionation of starch, a linear polymer called amylose, is obtained. Starch also shows a branched polymer called amylopectin, the bond at the branch point is a ⁇ (1->6) bond.
- Another carbohydrate polymer showing the same polymerization structure is glycogen. In vivo there are enzymes capable to degrade starch to glucose. This degradation in the body is performed by an enzyme called ⁇ -amylase, showing specificity for ⁇ (1->4) bonds.
- this invention is not restricted to the use of the above mentioned carbohydrates, although these are the preferred ones.
- Other types of carbohydrates which easily maybe applicated for the person skilled in the art, includes e.g. cellulose, chitosan, alginate, xantan, dextran, agarose, carrageenan, synthetic polymers or some derivative of these.
- guar gums locust bean gum (galacto-mannan), gum arabicum, tragacanth gum, karaya gum as well as derivatives of these.
- heteropolysaccarides of glucose, galactose, mannose, glucuroic acid and fucose (Biopolymer PS-87, Lever Brothers Company, USA; US Patent 4,357,423) maybe used according to this invention. These carbohydrate monomers are linked together by glycosidic bonds which may be hydrolyzed into smaller fragment which then maybe excreted via the kidneys.
- PLGA microspheres mainly are produced according to this technology (US Patent 4,389,930).
- Precipitation systems are described in PCT/SE83/00268 where the polymer used id starch, polymerization systems is described using starch (SE 7407461-8) or different kinds of microspheres based on acrylic polymers (J.Pharm.Sci. 1980, 69, 838-842). Also complexes and solutions are described (Swedish patent application 8501094.0) as useful formulations within this area.
- a preformed polymer is used which is crosslinked. This separates the present invention from the majority of technologies used for the production of microspheres where the starting material are the monomers which are linked together, forming a three dimensional network using various chemical reagents.
- abifunctional reagents examples include epoxides (e-g. epichlorohydrine or various types of bisepoxides).
- This type of reaction takes advantage of the hydroxyl groups on the carbohydrate polymer and has been used in the known technology of producing carbohydrate microspheres (e.g. Sephadex®, Sepharose® and Spherex ⁇ ).
- carbohydrate microspheres e.g. Sephadex®, Sepharose® and Spherex ⁇
- the epoxide crosslink is not regarded as a biodegradable bond.
- this type of crosslinking may not be used in the production of microspheres containing metal ions or metal oxides of the transition elements (e.g, Fe, Ni and Cr) since the epoxide primarily reacts with the Lewis acids formed, and not the carbohydrate.
- microspheres are primarily performed using emulsion technologies. This means, using carbohydrates, that the polymer is dissolved in an hydrophilic solvent (e.g. water), whereafter this solution is emulsified in a suitable hydrophobic phase which not is mixable with the carbohydrate solution. As a result, after mixing, small droplets of the carbohydrate solution is formed in the hydrophobic phase.
- a surfactant such a substance has the ability of forming a stable boundary between the two phases. Schematically, such a surfactant has two surfaces - one hydrophilic and one hydrophobic - thus forming the stabilization layer between the two phases.
- microspheres As a contrast agent or at inhalation (i.e. as a spray) is their ability to be suspendable as a monodispers suspension in a physiological water solution. This is conventionally performed using surfactants. However, using the present invention, a negatively charged microsphere is obtained which is optimal in order to avoid aggregation.
- the invention also presents a procedure for the preparation of superparamagnetic microspheres which constitutes of a crosslinked biologically acceptable polymer into which a magnetically responsive material, preferably a metal oxide, has been entrapped.
- the microspheres may be used as a contrast agent in medical diagnostics, in particular in Magnetic Resonance Tomography (MRT). It is also possible to use the microspheres as a matrix for biological molecules and thereby as a separation device. Further use for the microspheres is seen after combining the microspheres with drugs, after which the microspheres are injected into the blood stream and stopped at a predetermined site with the help of an external magnet (i.e. drug targeting).
- Magnetically responsive materials are available commercially and are described in the scientific literature. Preferentially used is however magnetite due to its cheap price, availability and stability in a water environment.
- Other materials that may be used includes inter alia Ni-NiO, Ni-TiO 4 , Mn-Fe ferrites, Ni, CoSm, Co, etc.
- superparamagnetic microspheres are obtained, indicating that they are not permanently magnetized when subjected to a magnetic field. Thus, the microspheres are easily resuspended into a monodispers suspension. Superparamagnetic microspheres are of utmost importance using the microspheres according to the present invention in order to avoid permanent aggregation
- Magnetic microspheres has for long times been discussed as the most effective system in biotech separations (Hirschbein et al, Chemtech, March 1982, 172-179).
- prior art within this area lacks one or several prerequisites in order for the technology to gain acceptance on the market.
- the above mentioned superparamagnetic property is thereby one of the most important.
- Ithakissios (US Patent 4,115,534. Sept.19, 1978) describes magnetic polymer microspheres in the size range of 10-100 ⁇ m, where the invention is exemplified using proteins or polyuretane as matrices with subsequent covalent crosshnking.
- Avrameas & Guesdon US Patent 4,241,176.
- Ugelstad et al (PCT/NO83/ 00014) describes a preparation procedure where the magnetic material is precipitated inside prefabricated polymer microspheres of a defined size.
- Czerlinski (US Patent 4,454,234. June 12, 1984) describes magnetite particles which has been surface coated with a crosslinked polymer of acrylamide.
- Molday (US Patent 4,452,773. Jun.5, 1984) describes way of producing magnetite particles having a size of 10-70 nm, surface coated with a dextran polymer.
- Schroder & Borrebaeck (EPC 83901116.0) describes entrappment of magnetite particles into a carbohydrate matrix by an emulsion process with subsequent stabilization by crystallization of the carbohydrate polymer.
- Chagnon et al (EPO 0 125 995) describes a process for the preparation of magnetite particles which in a subsequent step are surface coated with a silicon polymer,
- microspheres to be used in theses areas, must be simple to produce in large quantities combined with an equally simple way of attaching the affinity ligands.
- microspheres within biotech separation it is also a wish to have microspheres in this range due to the high surface to volume ratio obtained. For example, reducing the size of a particle from 10 to 0.5 ⁇ m, the surface available for attachment of affinity ligands is enhanced 20 times, as calculated on a defined volume packed beads.
- the size should not be below 0,3 ⁇ m since the magnetically responsive microsphere thereby contains too small amounts of magnetic material in order to be influenced by the magnetic field. Furthermore, with microspheres below this size particle/liquid interactions appear resulting in a suspension behaving more like a magnetic liquid thereby omitting the possibility of separating the discrete particles.
- microspheres are not stable and has to further processed in order to be used in the areas discussed above.
- spray technology there is the possibility to introduce the crosslinking agent in the gas phase.
- the invention is not restricted to the use of the mentioned methodologies for the different applications discussed above, the person skilled in the art may easily adopt the methods and use within other areas additives except the carbohydrates described. This is obtained by precipitation of iron salts into an alkali solution where iron oxide is formed. However, this is performed by allowing both the iron salts and a solution of the starch, simultanously to by added to the alkali solution while a powerful energy input is obtained by sonication.
- the suspension obtained containing a monodispers suspension of superparamagnetic particles in a neutral or alkali solution of carbohydrates, may now after concentration step, be emulsified in an organic solvent, a crosslinker maybe added leading to a stabilization of the microdroplet suspension into a water insoluble three dimensional polymer network.
- the ratio between the hydrophilic and the hydrophobic phase is 1:10.
- the emulsion is stirred in order to obtain the size of interest. After 60 minutes the emulsion is poured into 4 volumes of acetone, centrifuged and then washed another 5 times the same way. If the superparamagnetic microspheres are to be used for biotech separation, a tresyl activation is performed at this stage.
- STP sodiumtrimetaphosphate
- a biodegradable polymer starch
- a biodegradable crosslinking phosphate esters
- the present invention relies on the covalent crosslinking of a carbohydrate solution in an emulsion or to perform the crosslinking in a partially water containing environment of prefabricated microspheres.
- the process for fabrication of microspheres according to the present invention is based on the optimization of the parameters in order to achieve microspheres which all fulfills the requirements discussed above.
- the process, according to the present invention renders a high yield where secondary purification steps in order to achieve optimal microspheres having the adequate size is not necessary.
- a prerequisite in producing the superparamagnetic microspheres according to the present invention is that the magnetite particles to entrapped into the three dimensional polymeric network can be obtained as a stable suspension in an alkali solution or at neutral pH without any BSA was attached per mg of spheres.
- the spheres were suspended in physiological water solution (phosphate buffered saline, pH 7.4).
- the size was measured daily with the help of a Coulter Counter Multisizer ⁇ for four consecutive days with the following result.
Abstract
La présente invention se rapporte à un moyen de production de microsphères à liaison réticulée covalente au moyen de polymères biologiquement acceptables et à l'utilisation de ces microsphères.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8704158-8 | 1987-10-26 | ||
SE8704158A SE8704158L (sv) | 1987-10-26 | 1987-10-26 | Mikrosfaerer, foerfarande foer framstaellning daerav och anvaendning daerav |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989003674A1 true WO1989003674A1 (fr) | 1989-05-05 |
Family
ID=20370007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1988/000560 WO1989003674A1 (fr) | 1987-10-26 | 1988-10-24 | Microspheres, procede de production des microspheres et leur utilisation |
Country Status (2)
Country | Link |
---|---|
SE (1) | SE8704158L (fr) |
WO (1) | WO1989003674A1 (fr) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990006045A2 (fr) * | 1988-11-21 | 1990-06-14 | Dynal As | Sondes d'acide nucleique |
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
DE4406139A1 (de) * | 1994-02-25 | 1995-08-31 | Matthias Werner | Magnetische Depotarzneimittel für die perorale Applikation mit verbesserter Resorption der Wirkstoffe |
US5498421A (en) * | 1993-02-22 | 1996-03-12 | Vivorx Pharmaceuticals, Inc. | Composition useful for in vivo delivery of biologics and methods employing same |
US5512439A (en) * | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
US5650156A (en) * | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
US5665382A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5997904A (en) * | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US6340527B1 (en) * | 1997-07-01 | 2002-01-22 | Ato B.V. | Encapsulation of active ingredients |
US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US20100047895A1 (en) * | 2001-06-24 | 2010-02-25 | Hyglos Invest Gmbh | Methods for purification of bacterial cells and cell components |
AU2006246478B2 (en) * | 2000-01-21 | 2010-09-30 | Nordiag Asa | Cell isolation method |
WO2010142960A1 (fr) * | 2009-06-10 | 2010-12-16 | Dna Supernova Ltd | Microsphères d'amplification de signal, leurs utilisations dans des procédures d'amplification analytique à une étape et à multiples étapes et leurs procédés de production |
US20120003321A1 (en) * | 2008-12-25 | 2012-01-05 | Xi'an Goldmag Nanobiotech Co. Ltd. | Crosslinked Dextran Composite Magnetic Microparticles and Preparation Process and Using Method Thereof |
WO2019037743A1 (fr) * | 2017-08-22 | 2019-02-28 | 中国石油化工股份有限公司 | Microsphère contenant de l'amidon et procédé de préparation s'y rapportant et son application |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0184710A2 (fr) * | 1984-12-08 | 1986-06-18 | Bayer Ag | Microsphères magnétiques |
-
1987
- 1987-10-26 SE SE8704158A patent/SE8704158L/xx not_active Application Discontinuation
-
1988
- 1988-10-24 WO PCT/SE1988/000560 patent/WO1989003674A1/fr unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0184710A2 (fr) * | 1984-12-08 | 1986-06-18 | Bayer Ag | Microsphères magnétiques |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990006045A3 (fr) * | 1988-11-21 | 1991-03-21 | Holmes Michael John | Sondes d'acide nucleique |
US5512439A (en) * | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
WO1990006045A2 (fr) * | 1988-11-21 | 1990-06-14 | Dynal As | Sondes d'acide nucleique |
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5498421A (en) * | 1993-02-22 | 1996-03-12 | Vivorx Pharmaceuticals, Inc. | Composition useful for in vivo delivery of biologics and methods employing same |
US5650156A (en) * | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
US5665382A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5997904A (en) * | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
DE4406139A1 (de) * | 1994-02-25 | 1995-08-31 | Matthias Werner | Magnetische Depotarzneimittel für die perorale Applikation mit verbesserter Resorption der Wirkstoffe |
US6340527B1 (en) * | 1997-07-01 | 2002-01-22 | Ato B.V. | Encapsulation of active ingredients |
AU2006246478B2 (en) * | 2000-01-21 | 2010-09-30 | Nordiag Asa | Cell isolation method |
US7964364B2 (en) * | 2000-01-21 | 2011-06-21 | Nordiag Asa | Cell isolation method |
US20100047895A1 (en) * | 2001-06-24 | 2010-02-25 | Hyglos Invest Gmbh | Methods for purification of bacterial cells and cell components |
US8932580B2 (en) * | 2001-06-24 | 2015-01-13 | Hyglos Invest Gmbh | Methods for purification of bacterial cells and cell components |
US20120003321A1 (en) * | 2008-12-25 | 2012-01-05 | Xi'an Goldmag Nanobiotech Co. Ltd. | Crosslinked Dextran Composite Magnetic Microparticles and Preparation Process and Using Method Thereof |
WO2010142960A1 (fr) * | 2009-06-10 | 2010-12-16 | Dna Supernova Ltd | Microsphères d'amplification de signal, leurs utilisations dans des procédures d'amplification analytique à une étape et à multiples étapes et leurs procédés de production |
US9151748B2 (en) | 2009-06-10 | 2015-10-06 | Supernova Diagnostics, Inc. | Signal amplification microspheres, their use in one-step and multi-step analytical amplification procedures and methods for their production |
US10048257B2 (en) | 2009-06-10 | 2018-08-14 | Supernova Diagnostics, Inc. | Signal amplification microspheres, their use in one-step and multi-step analytical amplification procedures and methods for their production |
WO2019037743A1 (fr) * | 2017-08-22 | 2019-02-28 | 中国石油化工股份有限公司 | Microsphère contenant de l'amidon et procédé de préparation s'y rapportant et son application |
US11891458B2 (en) | 2017-08-22 | 2024-02-06 | China Petroleum & Chemical Corporation | Starch-containing microsphere and preparation method and use thereof |
Also Published As
Publication number | Publication date |
---|---|
SE8704158D0 (sv) | 1987-10-26 |
SE8704158L (sv) | 1989-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1989003674A1 (fr) | Microspheres, procede de production des microspheres et leur utilisation | |
US4871716A (en) | Magnetically responsive, hydrophilic microspheres for incorporation of therapeutic substances and methods of preparation thereof | |
Assa et al. | Chitosan magnetic nanoparticles for drug delivery systems | |
EP0688429B1 (fr) | Microparticules macromoleculaires et procedes de preparation | |
Kakar et al. | Magnetic microspheres as magical novel drug delivery system: A review | |
US5547682A (en) | Preparation and use of novel injectable RES avoiding inorganic particles for medical application | |
US4671954A (en) | Microspheres for incorporation of therapeutic substances and methods of preparation thereof | |
EP1509246B1 (fr) | Support polymere thermosensible a structure physique pouvant etre modifiee, pour l'analyse biochimique, le diagnostic et la therapie | |
CN101164621B (zh) | 超顺磁性复合微粒载药体及其制备方法 | |
US20060188562A1 (en) | Materials and methods for drug delivery and uptake | |
US20060270030A1 (en) | Multimodally altered cells as a form for administering active substances and as diagnostic particles | |
NO314785B1 (no) | Jernholdige nanopartikler med dobbelt belegning og deres anvendelse i diagnostikk og terapi | |
CN100573747C (zh) | 纳米磁性微球的制备方法 | |
WO1988007870A1 (fr) | Procede de piegeage de substances biologiquement actives et son utilisation | |
Haniffa et al. | Cellulose supported magnetic nanohybrids: Synthesis, physicomagnetic properties and biomedical applications-A review | |
Smith et al. | Worm-like superparamagnetic nanoparticle clusters for enhanced adhesion and magnetic resonance relaxivity | |
CN103769018A (zh) | 改性凝集素包裹的磁性大分子脂质体纳米微球、制备方法及应用 | |
WO1989003675A1 (fr) | Particules superparamagnetiques, moyen de production de telles particules et leur utilisation | |
CN105478087B (zh) | 一种基于涂覆葡聚糖的羧基磁珠的制备方法及其应用 | |
Wu et al. | Heparinized magnetic mesoporous silica nanoparticles as multifunctional growth factor delivery carriers | |
JP2003512336A (ja) | 磁気標的化キャリア | |
Shen et al. | Encapsulation of recombinant cells with a novel magnetized alginate for magnetic resonance imaging | |
WO2006042724A2 (fr) | Particules magnetiques utilisables en therapie et pour le diagnostic | |
CN109125295A (zh) | 一种齐墩果酸接枝的壳聚糖载药纳米颗粒及其制备和应用 | |
CN113648426A (zh) | 一种能双向连接磁性纳米粒的构建方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |